摘要: 小编：心血管、糖尿病、哮喘、银血病……包括睡眠类药物，一直都是兵家必争之地，因为这些病是慢性病，发病率高，长期服药，还没办法根治…… 毫无疑问，这次默克又挖到金矿了。 以下是新闻稿： Merck's sleep dr ...
| 小编：心血管、糖尿病、哮喘、银血病……包括睡眠类药物，一直都是兵家必争之地，因为这些病是慢性病，发病率高，长期服药，还没办法根治…… 毫无疑问，这次默克又挖到金矿了。 以下是新闻稿： Merck's sleep drug suvorexant overcomes hurdles to win FDA approval August 14, 2014 | By Arlene Weintraub Merck ($MRK) scored a muted victory on Wednesday when the FDA approved its insomnia remedy suvorexant at four doses--the largest of which is half what the company initially hoped to be able to market. The drug, which will be sold under the brand name Belsomra, was initially rejected by the FDA a year ago because of concerns that at high doses, it could cause next-day drowsiness and raise the risk of car crashes. The FDA said it asked Merck to do driving studies with patients taking what would ultimately become the largest approved dose, 20 mg, and the agency was concerned about the results. "The testing showed impaired driving performance in both male and female participants when the 20-mg strength was taken," a statement from the FDA said. "Patients using the 20 mg-strength should be cautioned against next-day driving or activities requiring full mental alertness." Analysts expect that the FDA's cautiousness will limit Belsomra's market potential. The drug is now expected to bring in about $305 million in sales in 2017, compared to the $516 million that was forecast prior to the FDA's negative verdict last year, according to 6 analyst estimates compiled by Bloomberg. Belsomra is the first FDA-approved insomnia drug that works by targeting orexins, chemicals in the brain that promote wakefulness. Other widely used sleeping pills, such as Sanofi's ($SNY) Ambien and Sumitomo Dainippon Pharma's Lunesta, work instead by inhibiting GABA--a mechanism of action that promotes sleep but that can also interfere with memory, attention, and cognition. Last spring, Merck scientists told the media they had animal studies showing that Belsomra was less likely to cause those adverse events, but the FDA isn't buying it: The statement warns that the drug is just as likely to cause people to perform complex tasks while not fully awake, such as driving, eating, and making phone calls. That warning, coupled with the low approved doses, could make it challenging for Merck to compete against older sleep medicines, many of which are available as generics. Sales of sleep aids totaled $1.5 billion last year, with the bulk of prescriptions being written for generic Ambien, according to data compiled by Bloomberg. Merck has made it clear it's counting on much more than Belsomra to boost its top and bottom lines. During the company's recent quarterly earnings call, R&D chief Roger Perlmutter instructed analysts to focus on the company's plans to boost its research spending in the second half of the year. Among the potential upcoming milestones Perlmutter cited were Merck's accelerated filing for its PD-1 immuno-oncology drug pembrolizumab and its plans to speed up a hep C trial combining two Merck drugs with Gilead's ($GILD) runaway blockbuster Sovaldi. |
我们提供专业的服务， 从产品定位、机械的生产制造，我们 实力出众，只因我们更努力
公司生产的生物反应器及各种配套设备，可替代国外同类产品的垄断，并帮助企业节省生产成本，同时提供生产过程中各种技术支持。
我们一如既往地根据用户的需求、市场环境、企业状况等进行综合分析并提供真实可靠的解决方案，迄今为止服务上千家企业。
我们将致力于优质的技术服务确保每个机械设备的安全，用更成熟的方案解决每一个问题，为企业提供一站式服务。
